0.740
-0.075
(-9.20%)
Real-time:
8:58am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 0.74 - 0.78 |
| 52 week | 0.66 - 1.60 |
| Open | 0.81 |
| Vol / Avg. | 1.10M/2.09M |
| Mkt cap | 23.36M* |
| P/E | - |
| Div/yield | - |
| EPS | 0.00* |
| Shares | 3,156.84M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q1 (Jan '13) | 2012 | |
| Net profit margin | -70.17% | -35.34% |
| Operating margin | -84.70% | -52.46% |
| EBITD margin | - | -44.86% |
| Return on average assets | -8.99% | -7.18% |
| Return on average equity | -9.71% | -7.79% |
| Employees | 64 | - |
| Carbon Disclosure Rating | - | - |
Address
Unit 651, Street 5, Thorp Arch Estate
WETHERBY, ENG LS23 7FZ
United Kingdom - Map
+44-870-8354367 (Phone)
+44-870-8354368 (Fax)
WETHERBY, ENG LS23 7FZ
United Kingdom - Map
+44-870-8354367 (Phone)
+44-870-8354368 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Avacta Group plc is a provider of technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. It is engaged in the research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. The Company has two segments: Analytical and Animal Health. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Company�s subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited, TheraGenetics Limited and TheraGenetics Inc.
Officers and directors
| Alastair Smith Ph.D. | Chief Executive Officer, Executive Director | |
| Tim J. Sykes | Chief Financial Officer, Company Secretary, Executive Director | |
| Gwyn O. Humphreys | Independent Non-Executive Chairman of the Board | |
| Alan J. Aubrey | Independent Non-Executive Director | |
| Anthony Robards OBE | Independent Non-Executive Director |